Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper

Gut

Volumn 46, Issue 4, 2000, Pages 487-492

  Carty, E ^a   De Brabander, M ^b   Feakins, R M ^c   Rampton, D S ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Jan Palfijn Hospital   (Belgium)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Cytokines; Eicosanoids; Rectal dialysis; Ulcerative colitis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; ICOSANOID; INTERLEUKIN 1BETA; PROSTAGLANDIN E2; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; FEMALE; FILTER; HUMAN; HUMAN TISSUE; ICOSANOID METABOLISM; MALE; PRIORITY JOURNAL; RECTUM BIOPSY; RECTUM MUCOSA; ULCERATIVE COLITIS;

ADULT; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CYTOKINES; EICOSANOIC ACIDS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FILTRATION; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; RECTUM; SIGMOIDOSCOPY;

EID: 0034023467     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.46.4.487     Document Type: Article

References (45)

1. 1 Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 1994;106:533-9.
2. 2 Nielsen OH, Rask-Madsen J. Mediators of inflammation in chronic inflammatory bowel disease. Scand J Gastroenterol Suppl 1996;216:149-59.
3. 3 Rampton DS, Hawkey CJ. Prostaglandins and ulcerative colitis. Gut 1984;25:1399-413.
4. 4 Rampton DS, Collins CE. Review article: thromboxanes in inflammatory bowel disease - pathogenic and therapeutic implications. Aliment Pharmacol Ther 1993;7:357-67.
5. 5 Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337:1029-35.
6. 6 Casellas F, Papo M, Guarner F, et al. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis. Eur J Gastroenterol Hepatol 1995;7:221-6.
7. 7 Roberts WG, Simon TJ, Berlin RG, et al. Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology 1997;112:725-32.
8. 8 Sharon P, Ligumsky M, Rachmilewitz D. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978;75:638-40.
9. 9 Hawkey CJ, Karmeli F, Rachmilewitz D. Imbalance of prostacyclin and thromboxane synthesis in Crohn's disease. Gut 1983;24:881-5.
10. 10 Gertner DJ, Rampton DS, Stevens TR, et al. Verapamil inhibits in-vitro leukotriene B4 release by rectal mucosa in active ulcerative colitis. Aliment Pharmacol Ther 1992;6: 163-8.
11. 11 Rachmilewitz D, Karmeli F, Eliakim R. Platelet-activating factor - a possible mediator in the pathogenesis of ulcerative colitis. Scand J Gastroenterol Suppl 1990;172:19-21.
12. 12 Ligumsky M, Simon PL, Karmeli F, et al. Role of interleukin 1 in inflammatory bowel disease - enhanced production during active disease. Gut 1990;31:686-9.
13. 13 Daig R, Andus T, Aschenbrenner E, et al. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut 1996;38:216-22.
14. 14 Rampton DS, Sladen GE, Youlten LJ. Rectal mucosal prostaglandin E2 release and its relation to disease activity, electrical potential difference, and treatment in ulcerative colitis. Gut 1980;21:591-6.
15. 15 Lauritsen K, Laursen LS, Bukhave K, et al. In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis, and Clostridium difficile colitis. Gastroenterology 1988;95:11-7.
16. 16 Sandle GI, Hayslett JP, Binder HJ. Effect of glucocorticoids on rectal transport in normal subjects and patients with ulcerative colitis. Gut 1986;27:309-16.
17. 17 Rampton DS, Murdoch RD, Sladen GE. Rectal mucosal histamine release in ulcerative colitis. Clin Sci 1980;59: 389-91.
18. 18 Casellas F, Borruel N, Papo M, et al. Antiinflammatory effects of enterically coated amoxicillin-clavulanic acid in active ulcerative colitis. Inflamm Bowel Dis 1998;4:1-5.
19. 19 Raab Y, Hallgren R, Knutson L, et al. A technique for segmental rectal and colonic perfusion in humans. Am J Gastroenterol 1992;87:1453-9.
20. 20 Hendel J, Nielsen OH, Madsen S, et al. A simple filter-paper technique allows detection of mucosal cytokine levels in vivo in ulcerative colitis. Interleukin-1 and interleukin-1-receptor antagonist. Dig Dis Sci 1996;41:1775-9.
21. 21 Reilly AA, Bellisario R, Pass KA. Multivariate discrimination for phenylketonuria (PKU) and non-PKU hyperphenylalaninemia after analysis of newborns' dried blood-spot specimens for six amino acids by ion-exchange chromatography. Clin Chem 1998;44:317-26.
22. 22 Shibata M, Takano H, Hironaka T, et al. Detection of human cytomegalovirus DNA in dried newborn blood filter paper. J Virol Methods 1994;46:279-85.
23. 23 Offenbacher S, Farr DH, Goodson JM. Measurement of prostaglandin E in crevicular fluid. J Clin Periodontol 1981; 8:359-67.
24. 24 Baron J, Connell A, Lennard-Jones A. Variation between observers in describing mucosal changes in proctocolitis. BMJ 1964;1:89-92.
25. 25 Powell-Tuck J, Day DW, Buckell NA, et al. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982;27:533-7.
26. 26 Saverymuttu SH, Camilleri M, Rees H, et al. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology 1986; 90:1121-8.
27. 27 Bland M. Clinical measurement - repeatability and precision in measurement. In: Bland M, ed. An introduction to medical statistics, 3rd ed. Oxford: Oxford University Press, 1991:276-8.
28. 28 Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;i:307-10
29. 29 Casellas F, Borruel N, Papo M, et al. Usefulness of rectal dialysis to determine intrarectal eicosanoid release in ulcerative colitis. Rev Esp Enferm Dig 1997;89:280-8.
30. 30 Collins CE, Benson MJ, Burnham WR, et al. Picotamide inhibition of excess in vitro thromboxane B2 release by colorectal mucosa in inflammatory bowel disease. Aliment Pharmacol Ther 1996;10:315-20.
31. 31 Mahida YR, Lamming CE, Gallagher A, et al. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut 1991;32:50-4.
32. 32 Cappello M, Keshav S, Prince C, et al. Detection of mRNAs for macrophage products in inflammatory bowel disease by in situ hybridisation. Gut 1992;33:1214-19.
33. 33 Masuda H, Iwai S, Tanaka T, et al. Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. J Clin Lab Immunol 1995;46:111-23.
34. 34 Dionne S, Hiscott J, D'Agata I, et al. Quantitative PCR analysis of TNF-alpha and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies. Dig Dis Sci 1997;42:1557-66.
35. 35 Stevens C, Walz G, Singaram C, et al. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992;37: 818-26.
36. 36 Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992;103:1587-95.
37. 37 Sakai T, Kusugami K, Nishimura H, et al. Interleukin 15 activity in the rectal mucosa of inflammatory bowel disease. Gastroenterology 1998;114:1237-43.
38. 38 Raab Y, Gerdin B, Ahlstedt S, et al. Neutrophil mucosal involvement is accompanied by enhanced local production of interleukin-8 in ulcerative colitis. Gut 1993;34:1203-6.
39. 39 Casellas F, Papo M, Guarner F, et al. Intraluminal colonic release of immunoreactive tumour necrosis factor in chronic ulcerative colitis. Clin Sci 1994;87:453-8.
40. 40 Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
41. 41 Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease. Lancet 1999;353:459-61.
42. 42 Rask-Madsen J, Grove O, Hansen MG, et al. Colonic transport of water and electrolytes in a patient with secretory diarrhea due to collagenous colitis. Dig Dis Sci 1983;28: 1141-6.
43. 43 Goodman MJ, Skinner JM, Truclove SC. Abnormalities in the apparently normal bowel mucosa in Crohn's disease. Lancet 1976;1:275-8.
44. 44 Korelitz BI, Sommers SC. Rectal biopsy in patients with Crohn's disease. Normal mucosa on sigmoidoscopic examination. JAMA 1977;237:2742-4.
45. 45 O'Morain C, Bishop AE, McGregor GP, et al. Vasoactive intestinal peptide concentrations and immunocytochemical studies in rectal biopsies from patients with inflammatory bowel disease. Gut 1984;25:57-61.